Literature DB >> 18287011

The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors.

David Yin-Wei Lin1, Yoshimasa Tanaka, Masashi Iwasaki, Apostolos G Gittis, Hua-Poo Su, Bunzo Mikami, Taku Okazaki, Tasuku Honjo, Nagahiro Minato, David N Garboczi.   

Abstract

Signaling through the programmed death 1 (PD-1) inhibitory receptor upon binding its ligand, PD-L1, suppresses immune responses against autoantigens and tumors and plays an important role in the maintenance of peripheral immune tolerance. Release from PD-1 inhibitory signaling revives "exhausted" virus-specific T cells in chronic viral infections. Here we present the crystal structure of murine PD-1 in complex with human PD-L1. PD-1 and PD-L1 interact through the conserved front and side of their Ig variable (IgV) domains, as do the IgV domains of antibodies and T cell receptors. This places the loops at the ends of the IgV domains on the same side of the PD-1/PD-L1 complex, forming a surface that is similar to the antigen-binding surface of antibodies and T cell receptors. Mapping conserved residues allowed the identification of residues that are important in forming the PD-1/PD-L1 interface. Based on the structure, we show that some reported loss-of-binding mutations involve the PD-1/PD-L1 interaction but that others compromise protein folding. The PD-1/PD-L1 interaction described here may be blocked by antibodies or by designed small-molecule drugs to lower inhibitory signaling that results in a stronger immune response. The immune receptor-like loops offer a new surface for further study and potentially the design of molecules that would affect PD-1/PD-L1 complex formation and thereby modulate the immune response.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18287011      PMCID: PMC2268576          DOI: 10.1073/pnas.0712278105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine.

Authors:  T Okazaki; A Maeda; H Nishimura; T Kurosaki; T Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

2.  Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions.

Authors:  E Krissinel; K Henrick
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-11-26

Review 3.  The PD-1-PD-L pathway in immunological tolerance.

Authors:  Taku Okazaki; Tasuku Honjo
Journal:  Trends Immunol       Date:  2006-02-24       Impact factor: 16.687

4.  Crystallography & NMR system: A new software suite for macromolecular structure determination.

Authors:  A T Brünger; P D Adams; G M Clore; W L DeLano; P Gros; R W Grosse-Kunstleve; J S Jiang; J Kuszewski; M Nilges; N S Pannu; R J Read; L M Rice; T Simonson; G L Warren
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1998-09-01

5.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.

Authors:  H Nishimura; T Okazaki; Y Tanaka; K Nakatani; M Hara; A Matsumori; S Sasayama; A Mizoguchi; H Hiai; N Minato; T Honjo
Journal:  Science       Date:  2001-01-12       Impact factor: 47.728

6.  Restoring function in exhausted CD8 T cells during chronic viral infection.

Authors:  Daniel L Barber; E John Wherry; David Masopust; Baogong Zhu; James P Allison; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Nature       Date:  2005-12-28       Impact factor: 49.962

7.  Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.

Authors:  Manish J Butte; Mary E Keir; Theresa B Phamduy; Arlene H Sharpe; Gordon J Freeman
Journal:  Immunity       Date:  2007-07-12       Impact factor: 31.745

8.  A critical role for the programmed death ligand 1 in fetomaternal tolerance.

Authors:  Indira Guleria; Arezou Khosroshahi; Mohammed Javeed Ansari; Antje Habicht; Miyuki Azuma; Hideo Yagita; Randolph J Noelle; Anthony Coyle; Andrew L Mellor; Samia J Khoury; Mohamed H Sayegh
Journal:  J Exp Med       Date:  2005-07-18       Impact factor: 14.307

9.  Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction.

Authors:  Shengdian Wang; Jürgen Bajorath; Dallas B Flies; Haidong Dong; Tasuku Honjo; Lieping Chen
Journal:  J Exp Med       Date:  2003-04-28       Impact factor: 14.307

10.  Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Authors:  Y Ishida; Y Agata; K Shibahara; T Honjo
Journal:  EMBO J       Date:  1992-11       Impact factor: 11.598

View more
  133 in total

1.  PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1.

Authors:  Marguerite Ghiotto; Laurent Gauthier; Nacer Serriari; Sonia Pastor; Alemseged Truneh; Jacques A Nunès; Daniel Olive
Journal:  Int Immunol       Date:  2010-06-29       Impact factor: 4.823

2.  mRNA Display Discovery of a Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand for PD-L1).

Authors:  Golnaz Kamalinia; Brian J Engel; Anupallavi Srinivasamani; Brian J Grindel; Justin N Ong; Michael A Curran; Terry T Takahashi; Steven W Millward; Richard W Roberts
Journal:  ACS Chem Biol       Date:  2020-04-30       Impact factor: 5.100

3.  Prokaryotic expression of the extracellular domain of porcine programmed death 1 (PD-1) and its ligand PD-L1 and identification of the binding with peripheral blood mononuclear cells in vitro.

Authors:  Yan-Ping Zhu; Feng Yue; Yong He; Peng Li; Yuan Yang; Yu-Ting Han; Yan-Fang Zhang; Guo-Peng Sun; Dong-Guang Guo; Mei Yin; Xuan-Nian Wang
Journal:  Can J Vet Res       Date:  2017-04       Impact factor: 1.310

Review 4.  Sequence, structure, function, immunity: structural genomics of costimulation.

Authors:  Kausik Chattopadhyay; Eszter Lazar-Molnar; Qingrong Yan; Rotem Rubinstein; Chenyang Zhan; Vladimir Vigdorovich; Udupi A Ramagopal; Jeffrey Bonanno; Stanley G Nathenson; Steven C Almo
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

5.  Structures of PD-1 with its ligands: sideways and dancing cheek to cheek.

Authors:  Gordon J Freeman
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-23       Impact factor: 11.205

Review 6.  A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application.

Authors:  Taku Okazaki; Shunsuke Chikuma; Yoshiko Iwai; Sidonia Fagarasan; Tasuku Honjo
Journal:  Nat Immunol       Date:  2013-12       Impact factor: 25.606

Review 7.  Impact of the Protein Data Bank on antineoplastic approvals.

Authors:  John D Westbrook; Rose Soskind; Brian P Hudson; Stephen K Burley
Journal:  Drug Discov Today       Date:  2020-02-14       Impact factor: 7.851

8.  PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy.

Authors:  Xinyi Tu; Bo Qin; Yong Zhang; Cheng Zhang; Mohamed Kahila; Somaira Nowsheen; Ping Yin; Jian Yuan; Huadong Pei; Hu Li; Jia Yu; Zhiwang Song; Qin Zhou; Fei Zhao; Jiaqi Liu; Chao Zhang; Haidong Dong; Robert W Mutter; Zhenkun Lou
Journal:  Mol Cell       Date:  2019-04-30       Impact factor: 17.970

9.  Structure and T cell inhibition properties of B7 family member, B7-H3.

Authors:  Vladimir Vigdorovich; Udupi A Ramagopal; Eszter Lázár-Molnár; Eliezer Sylvestre; Jun Sik Lee; Kimberly A Hofmeyer; Xingxing Zang; Stanley G Nathenson; Steven C Almo
Journal:  Structure       Date:  2013-04-11       Impact factor: 5.006

10.  The molecular basis for modulation of human Vγ9Vδ2 T cell responses by CD277/butyrophilin-3 (BTN3A)-specific antibodies.

Authors:  Aparna Palakodeti; Andrew Sandstrom; Lakshmi Sundaresan; Christelle Harly; Steven Nedellec; Daniel Olive; Emmanuel Scotet; Marc Bonneville; Erin J Adams
Journal:  J Biol Chem       Date:  2012-07-30       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.